Background: Hepatocholangiocarcinoma (H-ChC) has the clinicopathological features of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) and is a more aggressive subtype of primary hepatic carcinoma than HCC or iCCA.
Methods: We sequenced 91,112 single-cell transcriptomes from 16 human samples to elucidate the molecular mechanisms underlying the coexistence of HCC and iCCA components in H-ChC.
Results: We observed two molecular subtypes of H-ChC at the whole-transcriptome level (CHP and CIP), where a metabolically active tumour cell subpopulation enriched in CHP was characterized by a cellular pre-differentiation property. To define the heterogeneity of tumours and their associated microenvironments, we observe greater tumour diversity in H-ChC than HCC and iCCA. H-ChC exhibits weaker immune cell infiltration and greater CD8 exhausted T cell (Tex) dysfunction than HCC and iCCA. Then we defined two broad cell states of 6,852 CD8 Tex cells: GZMK CD8 Tex cells and terminal CD8 Tex cells. GZMK CD8 Tex cells exhibited higher infiltration of after treatment in H-ChC, the effector scores and expression of the immune checkpoints of them greatly increased after immunotherapy, which indicated that H-ChC might be more sensitive than HCC or iCCA to immunotherapy.
Conclusions: In this paper, H-ChC was explored, hoping to contribute to the study of mixed tumours in other cancers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11336540 | PMC |
| http://dx.doi.org/10.21037/hbsn-23-400 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of metabolic reprogramming in liver cancer and its clinical perspectives.
Front Oncol
November 2024
Department of Gastrointestinal Minimally Invasive Surgery, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
Primary liver cancer (PLC), which includes hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), remains a leading cause of cancer-related death worldwide. Chronic liver diseases, such as hepatitis B and C infections and metabolic dysfunction-associated steatotic liver disease (MASLD), are key risk factors for PLC. Metabolic reprogramming, a defining feature of cancer, enables liver cancer cells to adapt to the demands of rapid proliferation and the challenging tumor microenvironment (TME).
View Article and Find Full Text PDFThe risk of cholangiocarcinoma in patients with MASLD is not increased compared to the general population.
Scand J Gastroenterol
November 2024
Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
Article Synopsis
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is becoming more common and is linked to serious health issues like liver cancer and cardiovascular disease.
- A study evaluated the risk of developing cholangiocarcinoma (CCA) in MASLD patients compared to a matched control group, using data from the Swedish National Patient Register over a span of 33 years.
- The results showed that only 0.1% of MASLD patients developed CCA, which is similar to the 0.3% occurrence in the general population, suggesting that there's no need for increased monitoring for CCA in MASLD patients.
Application of a single-cell-RNA-based biological-inspired graph neural network in diagnosis of primary liver tumors.
J Transl Med
October 2024
Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Article Synopsis
- Single-cell technology offers a more comprehensive view of tumors by analyzing both tumor cells and their surrounding microenvironments, potentially improving diagnosis compared to traditional methods that focus solely on pathology.
- Despite its advantages, single-cell RNA sequencing (scRNA-seq) faces significant issues, including complex data structures and low signal clarity, which hinder its diagnostic use.
- The authors introduce a graph neural network framework designed for diagnosing primary liver tumors by leveraging scRNA-seq data and intercellular communication networks, demonstrating accurate differentiation between malignant and benign tumors and validating their findings with public datasets.
The Dominant Component and Clinicopathological Characteristics of Combined Hepatocellular-cholangiocarcinoma After Radical Resection.
Anticancer Res
October 2024
Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Background/aim: Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a rare subtype of primary liver carcinoma, characterized by the unequivocal presence of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). However, its clinicopathological characteristics have not yet been thoroughly elucidated. In particular, cholangiolocellular carcinoma (CLC) was classified as a subtype of cHCC-CCA according to the 2010 World Health Organization (WHO) classification.
View Article and Find Full Text PDFUnveiling novel serum biomarkers in intrahepatic cholangiocarcinoma: a pilot proteomic exploration.
Front Pharmacol
September 2024
Department of Proteomics and Metabolomics, Institute of Medical Research and Life Sciences - Medfuture, "Iuliu Haţieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Article Synopsis
- * Using high-throughput mass spectrometry, the study identified 845 proteins, highlighting significant differences in protein levels among the conditions, with S100A9 and haptoglobin elevated in iCCA and ICAM2 in HCC.
- * Key findings suggest that serum amyloid A proteins (SAA1 and SAA4) as well as VCAM-1 and TEK may serve as potential biomarkers for distinguishing iCCA and HCC, emphasizing the need for further validation of these findings.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!